Contribution of host-derived tissue factor to tumor neovascularization

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 11, 2008, Pages 1975-1981

  Yu, Joanne ^a,b   May, Linda ^a   Milsom, Chloe ^a   Anderson, G Mark ^c   Weitz, Jeffrey I ^a   Luyendyk, James P ^d   Broze, George ^e   Mackman, Nigel ^f   Rak, Janusz ^a,g,h  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTOCOR INC   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g MONTREAL CHILDREN S HOSPITAL   (Canada)

^h RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Angiogenesis; Cyclophosphamide; Microvesicles; Tissue factor; Tumor

Indexed keywords

CYCLOPHOSPHAMIDE; THROMBOPLASTIN; ALKYLATING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; CANCER CELL; CANCER GRAFT; CARCINOGENESIS; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TOLERANCE; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG CARCINOMA; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN SIZE; TERATOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; CANCER STEM CELL; CELL SURVIVAL; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; EXPERIMENTAL MELANOMA; LEWIS CARCINOMA; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SECRETORY VESICLE; TIME; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOPHOSPHAMIDE; EMBRYONIC STEM CELLS; ENDOTHELIAL CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; SECRETORY VESICLES; TERATOMA; THROMBOPLASTIN; TIME FACTORS;

EID: 55449108080     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.175083     Document Type: Article

References (37)

1. Dvorak FH, Rickles FR. Malignancy and Hemostasis. In: Coleman RB, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Company Williams & Wilkins. 2006:851-873.
2. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006;35:103-110.
3. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice. J Clin Invest. 1994;94:1320-1327.
4. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SG, Pribluda VS. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003;63;2997-3000.
5. Ngo CV, Picha K, McCabe F et al. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer. 2007;120:1261-1267.
6. Yu JL, May L, Lhotak V, Shahrzad, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734-1741.
7. Toomey JR, Kratzer KE, Lasky NM, Broze GJ, Jr. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci U S A. 1997;94:6922-6926.
8. Palumbo JS, Talmage KE, Massari JV, LaJeunesse CM, Flick MJ, Kombrinck KW, Jarouskova M, Degen JL. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007;110:133-141.
9. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2:209-215.
10. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003;124:58S-68S.
11. Ruf W. Redundant signaling of tissue factor and thrombin in cancer progression? J Thromb Haemost. 2007;5:1584-1587.
12. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800-1814.
13. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:1687-93.
14. Belting M, Dorrell MI, Sandgren S, Aquilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W. Regulation of angio-genesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004;10:502-509.
15. Lazarus RA, Olivero AG, Eigenbrot C, Kirchhofer D. Inhibitors of Tissue Factor. Factor VIIa for anticoagulant therapy. Curr Med Chem. 2004;11:2275-2290.
16. Parry GC, Erlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest. 1998;101:560-569.
17. Hegmann EJ, Bauer HC, Kerbel RS. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res. 1992;52:6969-6975.
18. Klement H, St Croix B, Milsom C, May LJ, Guo Q, Yu JL, Klement P, Rak J. Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. Am J Pathol. 2007;171:1342-1351.
19. Kalas W, Yu JL, Milsom C, Rosenfeld J, Benezra R, Bornstein P, Rak J. Oncogenes and angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant Ras. Cancer Res. 2005;65:8878-8886.
20. Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL. Heterogeneous vascular dependence of tumor cell populations. Am J Pathol. 2001;158:1325-1334.
21. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003;100:12917-12922.
22. Aslakson CJ, Rak JW, Miller BE, Miller FR. Differential influence of organ site on three subpopulations of a single mouse mammary tumor at two distinct steps in metastasis. Int J Cancer. 1991;47:466-472.
23. Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J. 2003;22:4091-4102.
24. Mewhort-Buist TA, Liaw P, Patel S, Atkinson HM, Berry LR, Chan AK. Treatment of endothelium with the chemotherapy drug vincristine affects protein C generation in newborn plasma to a greater degree than in adult plasma. Thromb Res. 2008;122:418-426.
25. Feraud O, Cao Y, Vittet D. Embryonic stem cell-derived embryoid bodies development in collagen gels recapitulates sprouting angiogenesis. Lab Invest. 2001;81:1669-1681.
26. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003;3:411-421.
27. Giesen PL, Rauch U, Bohrmann B, Kling D, Rogue M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999;96:2311-2315.
28. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost. 2004;2:2065-2067.
29. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106:1604-1611.
30. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A. 1999;96:8663-8668.
31. Zhao J, Aguilar G, Deitcher SR, Funk WD. Abo A rNAPc2, a novel inhibitor of tissue factor/factor VIIa complex, suppresses lung metastasis and synergizes with 5-FU or bevacizumab in mouse models of colorectal cancer [abstract]. Blood 2006;108:321.
32. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W. Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008;111:190-199.
33. Milsom C, Anderson GM, Weitz JI, Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost. 2007;5:2550-2552.
34. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, DePauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404-407.
35. Kuenen BC, Levi M, Meijers JC, Kakkar AK, Van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 2002;22:1500-1505.
36. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007;7:475-485.
37. Ma L, Francia G, Viloria-Petit A, Hicklin D, du Manoir J, Rak J, Kerbel RS. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res. 2005;65:5365-5373.